Apuli Maricel reported tax withholding involving 4,714 shares of BridgeBio Pharma, Inc. at $79.86 for −$376k on Aug 16, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
Chief Accounting Officer
Chief Accounting Officer
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$376,460.04Shares × reported price
Shares traded
4,714Common Stock
Price per share
$79.86Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
122,687Direct
Trade date
Aug 16, 2026Tax withholding
Filed
Aug 18, 2026, 6:02 PM ET2-day reporting delay
Accession
0001470831-26-000835Code F · Transaction 4252
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

BBIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BBIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −1.9%1w ago +1.8%1d ago −3.8%
Returns since7d −2.7%30d −19%90d180d1y

Footnotes in full

F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,262 shares of Common Stock underlying the Reporting Person's RSUs.